Obermatt
See Similar Stocks →

Merck (DE)

GER:MRK · DE0006599905
PharmaceuticalsXX-Large

360

12
EV / EBIT27
Price / Owner Earnings48
Owner Earnings Yield49
Dividend Yield61
Price/Sales61
EV / Gross Profit52
Price/Book68
Return on Capital21
Cash Return on Capital24
Return on Equity27
EBIT Margin35
Gross Profitability18
Cash Conversion67
Accruals25
Owner Earnings Margin32
Sales growth16
Profit Growth88
Long-Term EPS Growth36
Owner Earnings Growth36
Reinvestment47
Price momentum56
Debt load43
Refinancing62
Debt Payback30
Liquidity60
Analyst ratings49
Opinion Changes38
Price Target Upside29
Market mood41
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Merck (DE) clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryGermany
IndustryPharmaceuticals
SizeXX-Large
TypePublic Company
ExchangeXTRA
Founded1995
Employees23,341
Websitemerckgroup.com
ISINDE0006599905
Last UpdateApr 2, 2026
Indices
CDAX (Germany)DAX 40 (Germany)
Themes
ImmunologyNeurologyHealth DiagnosticsCardiovascularGeneticsBiomedical EngineeringEndocrinologyBiomass EnergyOncologyBiotechnologyChemicalLife ScienceOrganic

Description

Merck KGaA presents a comprehensive portfolio spanning multiple business segments, namely Life Science, Healthcare, and Electronics. Business Segments The company presents a comprehensive portfolio spanning multiple business segments. The Life S…

Analysis

Weak and unloved

Merck KGaA is weak and unloved: below-average business metrics and a price that reflects that disappointment.

The price is fair. You pay 21.0× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 7% yearly growth; analysts expect 7%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
39
2023202420252026

All-time high

74

Jul 2025

All-time low

16

Jan 2024

Average rank

50

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
61
51
93
91
Price/Earnings
46
73
60
56
Price/Book
68
64
63
48
Dividend Yield
61
58
57
53
Value (overall)
65
92
85
70

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Merck (DE) with its peers
Ipsen
PAR:IPN
84
CountryFrance
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Lanxess
GER:LXS
4
CountryGermany
IndustryChemicals
SizeLarge
Full Stock Analysis →
Sanofi
PAR:SAN
91
CountryFrance
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Curatis Holding
SWX:CURN
70
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Sol-Gel Technologies
NAQ:SLGL
36
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →